Putting forward a model for the role of the cerebellum in cocaine-induced pavlovian memory.
DREADDs
cerebellum
cocaine
drug addiction
drug memory
Journal
Frontiers in systems neuroscience
ISSN: 1662-5137
Titre abrégé: Front Syst Neurosci
Pays: Switzerland
ID NLM: 101477946
Informations de publication
Date de publication:
2023
2023
Historique:
received:
30
01
2023
accepted:
25
05
2023
medline:
30
6
2023
pubmed:
30
6
2023
entrez:
30
6
2023
Statut:
epublish
Résumé
Substance Use Disorder (SUD) involves emotional, cognitive, and motivational dysfunction. Long-lasting molecular and structural changes in brain regions functionally and anatomically linked to the cerebellum, such as the prefrontal cortex, amygdala, hippocampus, basal ganglia, and ventral tegmental area, are characteristic of SUD. Direct and indirect reciprocal connectivity between the cerebellum and these brain regions can explain cerebellar roles in Pavlovian and reinforcement learning, fear memory, and executive functions. It is increasingly clear that the cerebellum modulates brain functions altered in SUD and other neuropsychiatric disorders that exhibit comorbidity with SUD. In the present manuscript, we review and discuss this evidence and present new research exploring the role of the cerebellum in cocaine-induced conditioned memory using chemogenetic tools (designer receptor exclusively activated by designer drug, DREADDs). Our preliminary data showed that inactivation of a region that includes the interposed and lateral deep cerebellar nuclei reduces the facilitating effect of a posterior vermis lesion on cocaine-induced preference conditioning. These findings support our previous research and suggest that posterior vermis damage may increase drug impact on the addiction circuitry by regulating activity in the DCN. However, they raise further questions that will also be discussed.
Identifiants
pubmed: 37388941
doi: 10.3389/fnsys.2023.1154014
pmc: PMC10303950
doi:
Types de publication
Journal Article
Langues
eng
Pagination
1154014Informations de copyright
Copyright © 2023 Melchor-Eixea, Guarque-Chabrera, Sanchez-Hernandez, Ibáñez-Marín, Pastor and Miquel.
Déclaration de conflit d'intérêts
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Références
Cell Rep. 2013 Apr 25;3(4):1239-51
pubmed: 23583179
J Neurosci. 2003 Dec 10;23(36):11461-8
pubmed: 14673011
Exp Neurol. 1976 Dec;53(3):714-28
pubmed: 1001395
Nat Neurosci. 2005 Nov;8(11):1481-9
pubmed: 16251991
J Neurosci. 2011 Jul 20;31(29):10463-73
pubmed: 21775592
Cell. 2015 Jul 30;162(3):622-34
pubmed: 26232228
Neuropharmacology. 2022 Nov 1;218:109210
pubmed: 35985392
Synapse. 2011 Nov;65(11):1204-12
pubmed: 21638338
Neuron. 2022 Apr 20;110(8):1290-1303
pubmed: 35325616
Behav Neurosci. 1990 Dec;104(6):934-47
pubmed: 2285492
Front Hum Neurosci. 2021 Sep 16;15:739175
pubmed: 34602998
J Clin Psychiatry. 2006;67 Suppl 8:7-12
pubmed: 16961424
Nature. 2021 Dec;600(7888):269-273
pubmed: 34789878
Drug Alcohol Depend. 2017 Apr 01;173:151-158
pubmed: 28259088
Exp Brain Res. 2001 Aug;139(3):278-86
pubmed: 11545466
J Neurosci. 2016 Nov 9;36(45):11459-11468
pubmed: 27911749
Proc Natl Acad Sci U S A. 2020 Mar 24;117(12):6855-6865
pubmed: 32152108
Eur J Neurosci. 2019 Aug;50(3):2613-2622
pubmed: 30280439
Nature. 2017 Apr 6;544(7648):96-100
pubmed: 28321129
Neurosci Lett. 2015 Sep 14;604:173-7
pubmed: 26219987
Acta Neuropsychiatr. 2016 Jun;28(3):141-8
pubmed: 26522275
Cerebellum. 2022 Oct;21(5):826-837
pubmed: 35752720
Front Behav Neurosci. 2019 May 07;13:99
pubmed: 31133834
Neuron. 2012 Jun 7;74(5):858-73
pubmed: 22681690
J Neurosci. 2015 Mar 11;35(10):4190-202
pubmed: 25762666
Cerebellum. 2019 Oct;18(5):922-931
pubmed: 31478166
Neuropsychopharmacology. 2002 Mar;26(3):376-86
pubmed: 11850152
Life Sci. 1999;64(9):775-84
pubmed: 10075110
Front Syst Neurosci. 2022 Jan 11;15:781527
pubmed: 35087384
Prog Brain Res. 2014;210:59-77
pubmed: 24916289
Behav Brain Res. 2009 Nov 5;203(2):256-63
pubmed: 19450624
Neuropharmacology. 2017 Oct;125:166-180
pubmed: 28712684
Cerebellum. 2019 Dec;18(6):1064-1097
pubmed: 31165428
Proc Natl Acad Sci U S A. 2002 Jun 11;99(12):8406-11
pubmed: 12034877
Nat Commun. 2020 Oct 15;11(1):5207
pubmed: 33060630
Alcohol Clin Exp Res. 2010 Aug;34(8):1306-18
pubmed: 20491734
Elife. 2019 Sep 11;8:
pubmed: 31509108
Psychopharmacology (Berl). 2000 Dec;153(1):31-43
pubmed: 11255927
Eur J Neurosci. 2007 May;25(9):2875-84
pubmed: 17466022
Prog Neuropsychopharmacol Biol Psychiatry. 2022 Jan 10;112:110429
pubmed: 34416354
Nat Rev Neurosci. 2018 Jun;19(6):338-350
pubmed: 29643480
Annu Rev Neurosci. 2006;29:565-98
pubmed: 16776597
Nat Neurosci. 2014 Dec;17(12):1767-75
pubmed: 25402853
Int Rev Neurobiol. 2013;113:1-34
pubmed: 24290381
J Neurosci. 2005 Aug 3;25(31):7150-8
pubmed: 16079397
Front Syst Neurosci. 2014 Feb 04;8:4
pubmed: 24550789
Biol Psychiatry. 2011 Jun 15;69(12):1178-84
pubmed: 20965496
Neurosci Biobehav Rev. 2016 Jan;60:1-11
pubmed: 26602022
Hum Brain Mapp. 2015 Jan;36(1):120-36
pubmed: 25142207
Biol Psychiatry Cogn Neurosci Neuroimaging. 2020 Apr;5(4):438-447
pubmed: 32033923
Curr Drug Abuse Rev. 2009 Jan;2(1):26-40
pubmed: 19630735
Brain. 1998 Apr;121 ( Pt 4):561-79
pubmed: 9577385
Nat Protoc. 2006;1(4):1662-70
pubmed: 17487149
Nat Methods. 2012 Jun 28;9(7):676-82
pubmed: 22743772
Addict Biol. 2014 Jan;19(1):61-76
pubmed: 23445190
J Comp Neurol. 2006 Feb 1;494(4):559-77
pubmed: 16374793
Nat Rev Neurosci. 2011 Oct 20;12(11):652-69
pubmed: 22011681
J Neurosci. 2022 Nov 9;42(45):8406-8415
pubmed: 36351826
Addict Biol. 2021 Jan;26(1):e12834
pubmed: 31808992
J Neurosci. 2001 Nov 1;21(21):8655-63
pubmed: 11606653
Aust N Z J Psychiatry. 2006 Feb;40(2):171-8
pubmed: 16476136
Neuropsychopharmacology. 2006 Jun;31(6):1318-26
pubmed: 16237382
J Neurosci Methods. 2006 Feb 15;151(1):62-7
pubmed: 16451810
Alcohol Clin Exp Res. 2021 Jun;45(6):1200-1214
pubmed: 33864389
Trends Cogn Sci. 2012 Jan;16(1):81-91
pubmed: 22155014
Cell. 2019 Apr 18;177(3):669-682.e24
pubmed: 30929904
Neuroimage. 2003 Jan;18(1):156-68
pubmed: 12507452
Front Behav Neurosci. 2020 Sep 29;14:582147
pubmed: 33132862
Am J Psychiatry. 2019 Jul 1;176(7):512-520
pubmed: 30696271
Neuron. 2014 Aug 6;83(3):518-32
pubmed: 25102558
Nat Neurosci. 2018 May;21(5):725-735
pubmed: 29662214
Eur J Pharmacol. 2000 Oct 27;407(1-2):91-100
pubmed: 11050295
Proc Natl Acad Sci U S A. 2009 Aug 4;106(31):13016-21
pubmed: 19651613
Proc Natl Acad Sci U S A. 2020 Jun 30;117(26):15253-15261
pubmed: 32541059
Nat Neurosci. 2020 Sep;23(9):1102-1110
pubmed: 32661395
Am J Psychiatry. 2001 Jul;158(7):1075-83
pubmed: 11431229
Indian J Psychiatry. 2019 Jan;61(Suppl 1):S9-S29
pubmed: 30745673
Front Syst Neurosci. 2020 Oct 21;14:586574
pubmed: 33192350
Eur J Neurosci. 2003 Feb;17(4):751-62
pubmed: 12603265
Brain Imaging Behav. 2020 Aug;14(4):1221-1229
pubmed: 30734203
Science. 2019 Jan 18;363(6424):
pubmed: 30655412
Proc Natl Acad Sci U S A. 2010 May 4;107(18):8452-6
pubmed: 20404184
J Neurosci. 2018 May 30;38(22):5182-5195
pubmed: 29760180
Nat Rev Neurosci. 2019 Aug;20(8):451-465
pubmed: 31263252
Cell Rep. 2021 Sep 21;36(12):109721
pubmed: 34551311
Proc Natl Acad Sci U S A. 1996 Oct 15;93(21):12040-5
pubmed: 8876259
J Neurosci. 2004 Dec 8;24(49):11017-22
pubmed: 15590917
Nature. 2018 Nov;563(7729):113-116
pubmed: 30333626
Subst Use Misuse. 2012 May;47(6):631-9
pubmed: 22329835
Prog Neuropsychopharmacol Biol Psychiatry. 2017 Apr 3;75:142-147
pubmed: 28185963
Addict Biol. 2014 May;19(3):317-31
pubmed: 24851284
Synapse. 1989;3(3):225-33
pubmed: 2718098
J Am Acad Child Adolesc Psychiatry. 2008 Jan;47(1):68-75
pubmed: 18174827
Prog Brain Res. 2002;137:333-49
pubmed: 12440376
Addict Biol. 2007 Sep;12(3-4):227-462
pubmed: 17678505
Physiol Behav. 2014 Jun 10;132:24-35
pubmed: 24813699
Neuroimage. 2005 Jul 15;26(4):1097-108
pubmed: 15886020